Scarica l'app Stockscreener
6.18
4.75%
0.28
Dopo l'orario di chiusura:
6.18
Precedente Chiudi:
$5.90
Aprire:
$5.84
Volume 24 ore:
829.35K
Relative Volume:
0.58
Capitalizzazione di mercato:
$476.89M
Reddito:
-
Utile/perdita netta:
$-168.09M
Rapporto P/E:
-2.8479
EPS:
-2.17
Flusso di cassa netto:
$-138.01M
1 W Prestazione:
+5.64%
1M Prestazione:
-21.17%
6M Prestazione:
-65.08%
1 anno Prestazione:
-64.75%
Intervallo 1D:
$5.776
$6.30
Intervallo di 1 settimana:
$5.64
$6.30
Portata 52W:
$5.41
$23.48
Kura Oncology Inc Stock (KURA) Company Profile
Nome
Kura Oncology Inc
Settore
Industria
Telefono
(858) 500-8800
Indirizzo
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Confronta KURA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
6.18 | 476.89M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-06 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-14 | Downgrade | Stifel | Buy → Hold |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-08-11 | Iniziato | BofA Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-05-17 | Iniziato | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2022-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Iniziato | Jefferies | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-07 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-11-05 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-11-09 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2016-10-13 | Ripresa | Leerink Partners | Outperform |
| 2016-01-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-12-30 | Iniziato | Oppenheimer | Outperform |
| 2015-12-16 | Iniziato | Citigroup | Buy |
Mostra tutto
Kura Oncology Inc Borsa (KURA) Ultime notizie
Renaissance Technologies LLC Acquires 491,700 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Shares Acquired by Vanguard Group Inc. - Defense World
American Century Companies Inc. Increases Stake in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Corebridge Financial Inc. Reduces Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology (NASDAQ:KURA) Earns Outperform Rating from Wedbush - Defense World
KLP Kapitalforvaltning AS Acquires New Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology stock holds $28 target, Market Outperform By Investing.com - Investing.com Canada
Kura Oncology's SWOT analysis: ziftomenib potential drives stock outlook - Investing.com
Kura Oncology’s SWOT analysis: ziftomenib potential drives stock outlook By Investing.com - Investing.com South Africa
Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Kura Oncology at Stifel Forum: Strategic Moves in Targeted Therapies By Investing.com - Investing.com Canada
Kura Oncology Submits Ziftomenib NDA to FDA for Treating Acute Myeloid Leukemia - MarketScreener
Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA - The Manila Times
Kura Oncology seeks FDA approval for leukemia drug - Investing.com
Kura Oncology seeks FDA approval for leukemia drug By Investing.com - Investing.com India
Breakthrough Cancer Drug for AML Reaches Major FDA Milestone: First-in-Class Treatment - Stock Titan
Kura Oncology stock hits 52-week low at $5.65 amid market challenges By Investing.com - Investing.com South Africa
Kura Oncology stock hits 52-week low at $5.65 amid market challenges - Investing.com India
28,748 Shares in Kura Oncology, Inc. (NASDAQ:KURA) Purchased by Thrivent Financial for Lutherans - Defense World
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology Strengthens Team: Strategic Stock Options Awarded to New Hires - Stock Titan
Kura Oncology (NASDAQ:KURA) Upgraded to “Buy” at StockNews.com - Defense World
Corient Private Wealth LLC Makes New $109,000 Investment in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Shares Bought by Teacher Retirement System of Texas - Defense World
Kura Oncology to Participate in Stifel Targeted Oncology Forum - The Manila Times
Kura Oncology CEO Set to Reveal Latest Cancer Treatment Strategy at Elite Stifel Forum - Stock Titan
Kura Oncology stock hits 52-week low at $6.75 amid market challenges - Investing.com India
Virtu Financial LLC Acquires New Position in Kura Oncology, Inc. (NASDAQ:KURA) - The AM Reporter
Virtu Financial LLC Makes New Investment in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology (NASDAQ:KURA) Upgraded by StockNews.com to “Buy” Rating - The AM Reporter
Kura Oncology (NASDAQ:KURA) Upgraded by StockNews.com to Buy Rating - Defense World
Kura Oncology presents promising preclinical data By Investing.com - Investing.com South Africa
Kura Oncology presents promising preclinical data - Investing.com India
Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting - The Manila Times
Charles Schwab Investment Management Inc. Buys 10,542 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology director Hasnain Faheem sells $181,456 in shares By Investing.com - Investing.com Australia
Insider Sell: Faheem Hasnain Sells 22,682 Shares of Kura Oncology Inc (KURA) - GuruFocus
Kura Oncology director Hasnain Faheem sells $181,456 in shares - Investing.com
Bank of New York Mellon Corp Decreases Stock Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Brokers Issue Forecasts for Kura Oncology FY2025 Earnings - Defense World
Kura Oncology (NASDAQ:KURA) Downgraded by StockNews.com to “Hold” - Defense World
US Bancorp DE Has $193,000 Stake in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
BTIG Research downgrades Kura Oncology Inc (KURA) stock to a Neutral - Knox Daily
Kura Oncology Inc (KURA) Q4 2024 Earnings: EPS of -$0.22 Beats E - GuruFocus.com
Kura Oncology at Leerink Conference: Strategic Advances in AML Therapies By Investing.com - Investing.com UK
Kura Oncology at Leerink Conference: Strategic Advances in AML Therapies - Investing.com
Kura Oncology stock hits 52-week low at $6.98 amid challenges - Investing.com Australia
Kura Oncology stock hits 52-week low at $6.98 amid challenges By Investing.com - Investing.com South Africa
Recent Research Analysts’ Ratings Changes for Kura Oncology (KURA) - Defense World
Kura Oncology Inc Azioni (KURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
4.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):